Skip to content

A prospective randomized clinical study on the effect of unilateral thoracic sympathectomy in the dominant hand verses bilateral R4 thoracic sympathectomy in the treatment of multi-site Primary palmar hyperhidrosis

A prospective randomized clinical study on the effect of unilateral thoracic sympathectomy in the dominant hand verses bilateral R4 thoracic sympathectomy in the treatment of multi-site Primary palmar hyperhidrosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058169
Enrollment
Unknown
Registered
2022-03-31
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical treatment of Primary palmar hyperhidrosis

Interventions

Experimental group:Unilateral R4 thoracic sympathectomy
Control group:Bilateral R4 thoracic sympathectomy

Sponsors

The Third People's Hospital Of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with multi-site moderate-to-severe Primary palmar hyperhidrosis who are willing to undergo surgery, specifically those with hand hyperhidrosis accompanied by sweating on two or more parts of the feet, armpits, or face; 2. Age 15-65 years old; 3. Patients who understand and can accept postoperative compensatory sweating and recurrence of postoperative dyshidrosis.

Exclusion criteria

Exclusion criteria: 1. Patients with recent endocrine diseases such as tuberculosis, malignant tumours, hyperthyroidism, or central hypothalamic diseases; 2. Autoimmune vasculitis, thoracic outlet syndrome, past suffering from empyema and tuberculosis, etc., which lead to dense adhesions of the pleura; 3. Patients with severe bradycardia whose ECG heart rate is less than 55 beats/min and atropine test is positive; 4. Serious organic diseases, including active infections or cardiovascular diseases; 5. Patients with poor liver and kidney reserve or severe liver cirrhosis, with abnormal blood coagulation indicators; 6. Cardiopulmonary function reserve who cannot tolerate surgery: Cardiac function > New York Heart Association (NYHA) Grade II. Lung function: FEV1<1.5L, MVV<50% of the predicted value; 7. Poor compliance, unable to complete the follow-up as planned; 8. The investigator believes that it is not suitable for patients participating in this trial.

Design outcomes

Primary

MeasureTime frame
Surgical effect;

Countries

China

Contacts

Public ContactShi Qinlang

The Third People's Hospital Of Shenzhen

shiqinlang@live.cn+86 13712258808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026